MANUEL
PRAGA TERENTE
Profesor emérito
Publicaciones (474) Publicaciones en las que ha participado algún/a investigador/a
2024
-
Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis
Kidney International, Vol. 105, Núm. 1, pp. 177-188
-
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis
Nephrology Dialysis Transplantation, Vol. 39, Núm. 2, pp. 328-340
2023
-
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876
-
Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD
Journal of the American Society of Nephrology : JASN, Vol. 34, Núm. 6, pp. 955-968
-
Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy
Kidney360, Vol. 4, Núm. 5, pp. 659-672
-
Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis
Nefrologia, Vol. 43, Núm. 1, pp. 6-47
-
Effect of Immunosuppressive Treatments on Kidney Outcomes After Gross Hematuria-Related Acute Kidney Injury in Older Patients With IgA Nephropathy
Kidney International Reports, Vol. 8, Núm. 8, pp. 1596-1604
-
Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy
Kidney International Reports, Vol. 8, Núm. 12, pp. 2754-2764
-
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
The Lancet, Vol. 402, Núm. 10417, pp. 2077-2090
-
Glomerular diseases in pregnancy: pragmatic recommendations for clinical management
Kidney International, Vol. 103, Núm. 2, pp. 264-281
-
Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification
Mayo Clinic Proceedings
-
Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification
Kidney International, Vol. 104, Núm. 6, pp. 1092-1102
-
Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation
Nephrology Dialysis Transplantation, Vol. 38, Núm. 1, pp. 222-235
-
Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan
Kidney International Reports, Vol. 8, Núm. 4, pp. 860-870
-
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
The Lancet, Vol. 401, Núm. 10388, pp. 1584-1594
-
Targeting complement in IgA nephropathy
Clinical Kidney Journal, Vol. 16, pp. ii28-ii39
-
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
The Lancet Rheumatology, Vol. 5, Núm. 8, pp. e451-e460
-
Thrombotic microangiopathy in patients with malignant hypertension
Nephrology Dialysis Transplantation, Vol. 38, Núm. 5, pp. 1217-1226
-
Why should genetic testing be incorporated into routine clinical practice in nephrology? The utility of specialized clinics. An emerging need
Nefrologia, Vol. 43, Núm. 2, pp. 161-166
2022
-
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
Kidney International, Vol. 101, Núm. 1, pp. 174-184